| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Ferrous bisglycinate does not have a defined pharmacological target. As a source of iron, it provides bioavailable ferrous iron (Fe²⁺) for hemoglobin synthesis and other iron-dependent processes. The glycine chelate enhances iron absorption and reduces gastrointestinal side effects.
|
|---|---|
| ln Vitro |
Ferrous bisglycinate (25–200 μM; 2 h) has no effect on the viability of Caco-2 cells[2]. The Caco-2 cells' ferritin level is increased by ferrous bisglycinate (25 μM; 2 h)[2].
In vitro, ferrous bisglycinate is a source of iron for cell culture studies. It can be used to study iron metabolism and the effects of iron on cellular processes. Its chelated form may offer advantages over other iron salts in terms of solubility and bioavailability. |
| ln Vivo |
Mice treated with ferrous bisglycinate (500 mg/kg iron; po) do not develop colitis[3].
In vivo, ferrous bisglycinate is an effective iron supplement. It is efficiently absorbed by the body and has a reduced likelihood of causing digestive discomfort. It is used to treat iron deficiency anemia and to prevent iron deficiency in individuals with dietary limitations. |
| Enzyme Assay |
Non-cellular assays for ferrous bisglycinate involve measuring its iron content and chelation properties. The compound can be characterized using techniques such as atomic absorption spectroscopy or inductively coupled plasma mass spectrometry (ICP-MS).
|
| Cell Assay |
Cell Viability Assay[2]
Cell Types: Caco-2 cells Tested Concentrations: 0, 25, 50, 100, 200 μM Incubation Duration: 2 hrs (hours) Experimental Results: Did not affect the viability of wild-type and divalent metal transporter 1 (DMT1) knockout Caco-2 cells . Western Blot Analysis[2] Cell Types: Caco-2 cells Tested Concentrations: 25 μM Incubation Duration: 2 hrs (hours) Experimental Results: Increased ferritin content and diminished DMT1 expression levels Dramatically in the wild-type cells. Cell-based assays for ferrous bisglycinate involve studying its effects on iron metabolism in cells. Cells can be treated with the compound, and changes in iron uptake, storage, and utilization can be assessed. |
| Animal Protocol |
Animal/Disease Models: Female C57BL/6 mice are induced colitis by dextran sodium sulfate (DSS)[3]
Doses: 500 mg/kg iron Route of Administration: Po (add to the diet) for 10 days Experimental Results: Had the best survival rates (100%). Caused the least body lost (9% body loss). In vivo animal experiments with ferrous bisglycinate involve administering the compound to animals to study its effects on iron status. Animal models of iron deficiency anemia can be used to evaluate the efficacy of the supplement. The oral LD50 in rats is 560 mg iron/kg. |
| ADME/Pharmacokinetics |
Ferrous bisglycinate is absorbed following oral administration. The glycine chelate enhances its absorption compared to other iron salts. It is transported in the blood and utilized for hemoglobin synthesis and other functions.
|
| Toxicity/Toxicokinetics |
Ferrous bisglycinate is generally well-tolerated. It has a reduced likelihood of causing digestive discomfort compared to other iron salts. However, high doses may cause gastrointestinal side effects. The oral LD50 in rats is 560 mg iron/kg.
|
| References |
|
| Additional Infomation |
Ferrous glycinate is a chelate that can be used as a dietary iron source. Ferrous glycinate reacts with glycine to form a cyclic structure, possessing both chelating and nutritional functions. It is found in foods for fortification and in supplements used to treat iron deficiency or iron-deficiency anemia.
See also: ...View more... Ferrous bisglycinate is a dietary supplement and an active pharmaceutical ingredient (API). It is used as a source of dietary iron. It is not an approved drug for the treatment of any specific disease but is used to prevent and treat iron deficiency. |
| Molecular Formula |
C4H6FEN2O4
|
|---|---|
| Molecular Weight |
201.95
|
| Exact Mass |
203.983
|
| CAS # |
20150-34-9
|
| PubChem CID |
9837124
|
| Appearance |
Light brown to green solid powder
|
| Boiling Point |
240.9ºC at 760 mmHg
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
11
|
| Complexity |
37.4
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(C(=O)[O-])N.C(C(=O)[O-])N.[Fe+2]
|
| InChi Key |
GIPOFCXYHMWROH-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/2C2H5NO2.Fe/c2*3-1-2(4)5;/h2*1,3H2,(H,4,5);/q;;+2/p-2
|
| Chemical Name |
2-aminoacetate;iron(2+)
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
0.1 M HCL: 2 mg/mL (9.90 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2 mg/mL (9.90 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication (<60°C).
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9517 mL | 24.7586 mL | 49.5172 mL | |
| 5 mM | 0.9903 mL | 4.9517 mL | 9.9034 mL | |
| 10 mM | 0.4952 mL | 2.4759 mL | 4.9517 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT06014983
Conditions:Pregnancy|Iron DeficiencyLink: https://clinicaltrials.gov/ct2/show/NCT04017598
Conditions:Anemia, Iron Deficiency|Anemia|Intestinal Inflammation|Inflammation|Intestine; ComplaintsLink: https://clinicaltrials.gov/ct2/show/NCT04477018
Conditions:Iron|Cerebral Blood Flow|Energy Metabolism|Cognitive Function
Title:Efficacy Evaluation of 16 Weeks' Dietary Supplementation With Iron Bis-glycinate Plus Vitamin C on Cognitive Function, Subjective Mood, Fatigue, Health and Well-being
Status:Completed
updateDate:2020-07-13
Ctid:NCT04469010
Link: https://clinicaltrials.gov/ct2/show/NCT04469010
Conditions:Cognitive Function and Mood|Non-anaemic Iron DeficiencyLink: https://clinicaltrials.gov/ct2/show/NCT03009578
Conditions:AnemiaProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
